A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma

The antiapoptotic protein myeloid cell leukemia sequence 1 (MCL-1) is highly expressed in many human cancers and has been implicated in the development of resistance to anti-cancer therapy. AMG 176 is a novel, selective, small molecule MCL-1 inhibitor. Here we report preliminary results from a phase 1, first-in-human trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of AMG 176 in relapsed or refractory multiple myeloma (RRMM).

Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2019 Category: Hematology Authors: Andrew Spencer, Aaron Seth Rosenberg, Andrzej Jakubowiak, Noopur Raje, Manik Chatterjee, Suzanne Trudel, Nizar J. Bahlis, David S. Siegel, Stefan Wilop, Simon J. Harrison, Murthy NagaKrishna, Shyeilla Dhuria, Antreas Hindoyan, Zach McIver, Haby Henary, Ph Source Type: research